DIPP seeks details on 3 cancer drugs for compulsory licensing

February 21, 2013 11:43 pm | Updated November 16, 2021 10:20 pm IST - NEW DELHI:

Kick starting the process for a possible issuance of compulsory licences for anti-cancer drugs, the Department of Industrial Policy and Promotion (DIPP) has sought details from the Health Ministry regarding three medicines sold by multi-nationals Roche and Bristol-Myers Squibb in India to make them affordable.

The Health Ministry had approached the DIPP last month for issuance of compulsory licences (CLs) for three anti-cancer drugs — trastuzumab, ixabepilone and dasatinib — which are very expensive.

“The DIPP has sent a set of 12-14 questions to the Health Ministry on Wednesday. The department wants more information on things such as the number of cancer patients in India; prices of these three drugs in the domestic and international markets; alternative drugs if available and the name of the manufacturers and the like,” sources told PTI.

The Health Ministry had expressed concerns over the exorbitant prices of the three drugs.

While one vial (of 50 ml) of 40 mg trastuzumab costs Rs.1.24 lakh, 60 tablets of 20mg each of dasatinib priced at Rs.1.17 lakh. Similarly, one vial of 45 mg of ixabepilone costs Rs.66,430.

The sources, however, said a decision on these three drugs, the patent for which are held by Swiss drug major Roche and U.S.-based drug maker Bristol-Myers Squibb, respectively, are unlikely to be taken in a hurry.

Under the Indian Patents Act, a CL can be issued for a drug if the medicine is deemed unaffordable by the government and grants permission to qualified generic drug makers to manufacture it.

As per the WTO agreement, a CL can be invoked by a national government allowing a company to produce a patented product without the consent of the patent owner in public interest.

Top News Today

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.